Forecasting the future regulatory climate for drug and device manufacturers (“Manufacturer(s)”) is much like forecasting the path of a tornado. Climatologists know the tornado will hit, but nobody can pinpoint where, when or how damaging the storm will be. The best way to assure survival is for everyone in its path to have, practice and follow an effective emergency preparedness plan.
Continue reading "Stormy Skies or Smooth Sailing Ahead for Drug and Device Manufacturers?"
In The Headlines
Sustainable Risk Management with Commercial Impact: Headlines from the 2015 DIA Marketing Pharmaceuticals Meeting
Ilyssa Levins | Center for Communication Compliance (CCC)
As a former public relations practitioner, I think in headlines. So here are five take-away messages from the DIA’s annual Marketing Pharmaceuticals meeting which took place a few weeks ago:
The Food and Drug Administration (FDA) continues to be concerned about drug and device company violations.
Continue reading "Sustainable Risk Management with Commercial Impact: Headlines from the 2015 DIA Marketing Pharmaceuticals Meeting"
Topic of Discussion
Christopher Parrella | The Health Law Offices of Anthony C. Vitale, P.A.
When it comes to reputation Big Pharma has some serious problems, at least according to the 2015 Harris corporate reputation poll. Pharmaceutical companies rank ninth out of 14 industries when it comes to respect – or a lack thereof.
There is no question that pharmaceutical companies provide an invaluable public service, but their reputation has been tarnished in recent years by the vast amount of illegal behavior for which many have been accused of engaging.
Continue reading "Consequences of Illegal Behavior in Pharma"